Advanced Pharmacovigilance Training Course

This course qualifies for 18 hours for your CPD records.
More about CPD

We can customise this course to meet the requirements of your organisation and deliver it at your location and/or online.

Contact us

• A Practical Guide to Writing Risk Management Plans (RMPs)
• A Practical Guide to Producing and Maintaining the PSMF

• Alfa Wassermann S.p.A.
• Abbott Laboratories GmbH
• Actelion Pharmaceutical Ltd
• Alfa Wassermann S.p.A.
• Amgros
• Bausch & Lomb Inc
• Bayer Turk Kimya San. Ltd. Sti
• Celgene
• CSL Behring AG
• Eisai Europe Ltd
• Eisai Limited
• Ethypharm
• Ewopharma International s.r.o.
• Ferrer Internacional
• Genzyme Europe BV
• Grunenthal GmbH
• Grupo Ferrer Internaional S.A.
• Jubilant Draximage Inc.
• Merck Serono
• MSD AH Innovation GmbH
• Mundipharma Research GmbH & Co Kg
• Napp Pharmaceutical Group Ltd
• OrPha Swiss GmbH
• Pierre Fabre Medicament
• Piramal Healthcare Ltd
• Pliva Croatia Ltd
• Roche
• Sanofi
• Syntaxin Ltd
• TEVA

“Very good webinar. Well structured, interactive questions, small group, advanced topics (not easy to find elsewhere), competent speaker, good platform.”

Bettina Isler, Medical Information Manager, OrPha Swiss GmbH, Mar 21

“Inspiring speaker. I was very excited about all the anecdotes that he told.
Overall a very rewarding course.”

Helle Ribjerg, Global Safety Specialist, LEO Pharma, Mar 21

“Great”

Sidse Schjøtz, Complinace Manager, ALK , Sep 20

“Generally very good and good to have the anecdotes from real life.”

Sanne Mathias, Head of Compliance, ALK , Sep 20

“Good course and the leader was very clear in what he wanted to say. Exercises were fun..”

Amrita Kang, drug safety scientist, GE healthcare, Sep 20

“Parts of the presentation especially Day 3 were informative as it was more tailored to my role. I enjoyed the talk of RMPs, PSURs and crisis management. A lot of basics however were covered in this 'advanced course' in the CT directive topic, would be nice just to state what's changed and what's not changed almost like presenting a gap analysis, instead of covering basic definitions such as definition of an SAE and SUSAR and investigator reporting timelines. There was a 2 minute discussion on Brexit related changes on Day 2 which could have been a formal session as a presentation as I found that very useful for my role.”

Maria Sajid, Safety Evaluation Scientist, Eisai Europe Ltd, Sep 20

“Very nice course - will recommend to colleagues”

Tina Rishoej Clausen, Global Safety Specialist, LEO Pharma, Sep 20

“I was hoping to get more knowledge about the topics listed in the course presentation and I actually got a lot more, as we were not only given information related to the legislation in force but also very useful examples of applicability and some non-compliance cases. The speaker is undoubtedly an expert in the field with excellent presentation skills of all the proposed topics, including the most complex ones from a regulatory point of view. His experience and his analytic method facilitated my understanding of some critical passages of the law. ”

Ilaria Gargano, Global Safety Specialist, Leo Pharma, Sep 19

“[Graeme] was a very good presenter with very good industry knowledge and experience. Very interactive sessions and answered all our questions.”

Smitha Bhat, Principal CMG Scientist, GlaxoSmithKline, Sep 19

“The speaker was able to make a dry topic really exciting and I particularly liked the interaction with the group.”

Margot Börgartz, Stewardship Manager, Bayer AG, Sep 19

“Overall, the best seminar I've attended in format, topics, and speaker. I had hoped to learn about PV in general and all the different reporting requirements and report types – I learned much more than that. The speaker was great and I particularly liked the real-life stories and examples.”

Jane Bateman, Senior Drug Safety Scientist, GE Healthcare, Sep 19

“Graeme has superb knowledge of the regulations and guidelines around pharmacovigilance and talks in a passionate and engaging manner. An excellent course that really gives the students a much better understanding of pharmacovigilance and the opportunity to share knowledge. The content was spot on and Graeme's presentation style was engaging. ”

Christopher Harper, Senior Medical Information Manager, Astellas Pharma Europe Ltd, Mar 19

“Great presentations, great time keeping, good balance between exercises and presentations”

Ida Mizera, Local Responsible Person for PV, Grunenthal Ltd, Mar 19

“The content of the course was excellent for an all round view of PV, the presentations were good and flowed from one aspect of PV to another. Graeme's passion and energy for drug safety was evident throughout the three days. I really enjoyed this course.”

Ciara Walsh, Head of Regulatory Affairs and Pharmacovigilance, Noden Pharma DAC, Mar 19

“Very valuable with real examples. I liked that future elements of PV regulation were pointed out and not just the current one.”

Dorthe Lundmark, Drug Safety Coordinator, Pharmacosmos A/S, Mar 19